Abstract
The chemokine receptor CCR4 is broadly expressed on cells of the immune system. It is known to play a central role in T cell migration to the thymus, and T cell maturation and education. In addition, CCR4 is known to modulate T cell migration to several sites of inflammation in the body, including the skin, and lungs. It is best known as a drug target for airway inflammation and atopic dermatitis, but cells expressing CCR4 are found in many inflammatory diseases. CCR4 small molecule antagonists have not yet reached the clinic, but at least one has been validated in an in vivo model. Here we review the current status of structurally novel CCR4 receptor antagonists.
Keywords: CCR4 antagonists, inflammation model, thiophenesulfonamide, Diaminopyrimidines, Thiazolidinones, Lactams
Current Topics in Medicinal Chemistry
Title: Antagonists of CCR4 as Immunomodulatory Agents
Volume: 6 Issue: 13
Author(s): Ashok V. Purandare and John E. Somerville
Affiliation:
Keywords: CCR4 antagonists, inflammation model, thiophenesulfonamide, Diaminopyrimidines, Thiazolidinones, Lactams
Abstract: The chemokine receptor CCR4 is broadly expressed on cells of the immune system. It is known to play a central role in T cell migration to the thymus, and T cell maturation and education. In addition, CCR4 is known to modulate T cell migration to several sites of inflammation in the body, including the skin, and lungs. It is best known as a drug target for airway inflammation and atopic dermatitis, but cells expressing CCR4 are found in many inflammatory diseases. CCR4 small molecule antagonists have not yet reached the clinic, but at least one has been validated in an in vivo model. Here we review the current status of structurally novel CCR4 receptor antagonists.
Export Options
About this article
Cite this article as:
Purandare V. Ashok and Somerville E. John, Antagonists of CCR4 as Immunomodulatory Agents, Current Topics in Medicinal Chemistry 2006; 6 (13) . https://dx.doi.org/10.2174/15680266106061335
DOI https://dx.doi.org/10.2174/15680266106061335 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Current Pharmaceutical Design N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Human Platelet Acetylcholinesterase Inhibition by Cyclophosphamide: A Combined Experimental and Computational Approach
CNS & Neurological Disorders - Drug Targets Genetic Chemoprotection with Mutant O6-Alkylguanine-DNA-Alkyltransferases
Current Gene Therapy Cytochrome P450 Retinoic Acid 4-Hydroxylase Inhibitors: Potential Agents for Cancer Therapy
Mini-Reviews in Medicinal Chemistry Equilibrative Nucleoside (ENTs) and Cationic Amino Acid (CATs) Transporters: Implications in Foetal Endothelial Dysfunction in Human Pregnancy Diseases
Current Vascular Pharmacology Transposable Elements in Cancer and Other Human Diseases
Current Cancer Drug Targets Molecular Modeling Applied to Anti-Cancer Drug Development
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenetics and the Pharmaceutical Industry
Current Pharmaceutical Design Update on MDS Therapy: From Famine to Feast
Cardiovascular & Hematological Agents in Medicinal Chemistry Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design Secondary Metabolites from Cordyceps Species and Their Antitumor Activity Studies
Recent Patents on Biotechnology Histone Methyltransferase Inhibitors: Novel Epigenetic Agents for Cancer Treatment
Current Medicinal Chemistry The Culture-Repopulating Ability Assays and Incubation in Low Oxygen: A Simple Way to Test Drugs on Leukaemia Stem or Progenitor Cells
Current Pharmaceutical Design Rational Design of CPP-based Drug Delivery Systems: Considerations from Pharmacokinetics
Current Pharmaceutical Biotechnology In Silico Analysis of Amino Acid Sequences in Relation to Specificity and Physiochemical Properties of Mesophilic and Thermophilic Antileukemic L-Asparaginases
Current Biotechnology Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance
Mini-Reviews in Medicinal Chemistry